The Potential Role of Torsemide in Optimizing Loop Diuretic Therapy for Heart Failure Patients

V. K Chopra; P. P Mohanan; Vijay Kher; Raja Ram Mantri; Rajan Isaacs; Uday Jadhav; Nitin Zalte; Amarnath Sugumaran; Senthilnathan Mohanasundaram

doi:10.7759/cureus.41957

journal article Jul 16, 2023

The Potential Role of Torsemide in Optimizing Loop Diuretic Therapy for Heart Failure Patients

V. K Chopra P. P Mohanan Vijay Kher Raja Ram Mantri Rajan Isaacs Uday Jadhav Nitin Zalte Amarnath Sugumaran Senthilnathan Mohanasundaram

Cureus · Springer Science and Business Media LLC

View at Publisher Save 10.7759/cureus.41957

Topics

No keywords indexed for this article. Browse by subject →

References

26

[1]

Huffman M, Prabhakaran D. Epidemiology and prevention in India. Natl Med J India. 2010, 23:283-8.

[2]

Singh A, Chauhan S, Devasia T, et al.. Financial burden of heart failure in a developing country: cost analysis from Manipal Heart Failure Registry, India. J Public Health (Berl). 2021, 29:585-94. 10.1007/s10389-019-01141-w 10.1007/s10389-019-01141-w

[3]

Mishra S, Mohan JC, Nair T, et al.. Management protocols for chronic heart failure in India. Indian Heart J. 2018, 70:105-27. 10.1016/j.ihj.2017.11.015 10.1016/j.ihj.2017.11.015

[4]

2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure

Paul A. Heidenreich, Biykem Bozkurt, David Aguilar et al.

Journal of Cardiac Failure 2022 10.1016/j.cardfail.2022.02.010

[5]

McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093/eurheartj/ehab368 10.1093/eurheartj/ehab368

[6]

Kurmani S, Squire I. Acute heart failure: definition, classification and epidemiology. Curr Heart Fail Rep. 2017, 14:385-92. 10.1007/s11897-017-0351-y 10.1007/s11897-017-0351-y

[7]

Vazir A, Cowie MR. Decongestion: diuretics and other therapies for hospitalized heart failure. Indian Heart J. 2016, 68 Suppl 1:S61-8. 10.1016/j.ihj.2015.10.386 10.1016/j.ihj.2015.10.386

[8]

Girerd N, Seronde MF, Coiro S, et al.. Integrative assessment of congestion in heart failure throughout the patient journey. JACC Heart Fail. 2018, 6:273-85. 10.1016/j.jchf.2017.09.023 10.1016/j.jchf.2017.09.023

[9]

Mullens W, Damman K, Harjola VP, et al.. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019, 21:137-55. 10.1002/ejhf.1369 10.1002/ejhf.1369

[10]

López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004, 43:2028-35. 10.1016/j.jacc.2003.12.052 10.1016/j.jacc.2003.12.052

[11]

López B, González A, Beaumont J, Querejeta R, Larman M, Díez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007, 50:859-67. 10.1016/j.jacc.2007.04.080 10.1016/j.jacc.2007.04.080

[12]

Friedel HA, Buckley MM. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs. 1991, 41:81-103. 10.2165/00003495-199141010-00008 10.2165/00003495-199141010-00008

[13]

Abraham B, Megaly M, Sous M, et al.. Impact of torsemide on cardiac remodeling and renin-angiotensin-aldosterone system in heart failure patients. J Am Coll Cardiol. 2020, 1:760. 10.1016/S0735-1097(20)31387-5 10.1016/s0735-1097(20)31387-5

[14]

Scheen AJ, Vancrombreucq JC, Delarge J, Luyckx AS. Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. Eur J Clin Pharmacol. 1986, 31 Suppl:35-42. 10.1007/BF00541465 10.1007/bf00541465

[15]

Cosin J, Díez J, TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002, 4:507-13. 10.1016/s1388-9842(02)00122-8 10.1016/s1388-9842(02)00122-8

[16]

Müller K. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life. Eur J Heart Fail. 2003, 5:793-801. 10.1016/s1388-9842(03)00150-8 10.1016/s1388-9842(03)00150-8

[17]

Balsam P, Ozierański K, Marchel M, et al.. Comparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: preliminary results from the randomized TORNADO trial. Cardiol J. 2019, 26:661-8. 10.5603/CJ.a2019.0114 10.5603/cj.a2019.0114

[18]

Täger T, Fröhlich H, Seiz M, Katus HA, Frankenstein L. READY: relative efficacy of loop diuretics in patients with chronic systolic heart failure-a systematic review and network meta-analysis of randomised trials. Heart Fail Rev. 2019, 24:461-72. 10.1007/s10741-019-09771-8 10.1007/s10741-019-09771-8

[19]

Mentz RJ, Anstrom KJ, Eisenstein EL, et al.. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the transform-HF randomized clinical trial. JAMA. 2023, 329:214-23. 10.1001/jama.2022.23924 10.1001/jama.2022.23924

[20]

Pitt B, Nicklas J. Loop diuretics in patients with heart failure: time to change to torsemide?. J Cardiovasc Pharmacol. 2009, 53:435-7. 10.1097/FJC.0b013e3181a71a78 10.1097/fjc.0b013e3181a71a78

[21]

Harada K, Izawa H, Nishizawa T, et al.. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol. 2009, 53:468-73. 10.1097/FJC.0b013e3181a717f7 10.1097/fjc.0b013e3181a717f7

[22]

Mentz RJ, Hasselblad V, DeVore AD, et al.. Torsemide versus furosemide in patients with acute heart failure (from the ASCEND-HF trial). Am J Cardiol. 2016, 117:404-11. 10.1016/j.amjcard.2015.10.059 10.1016/j.amjcard.2015.10.059

[23]

Murray MD, Deer MM, Ferguson JA, et al.. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001, 111:513-20. 10.1016/s0002-9343(01)00903-2 10.1016/s0002-9343(01)00903-2

[24]

Felker GM, O'Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?. Circ Heart Fail. 2009, 2:56-62. 10.1161/CIRCHEARTFAILURE.108.821785 10.1161/circheartfailure.108.821785

[25]

Yoshioka K, Maeda D, Okumura T, et al.. Clinical implication of initial intravenous diuretic dose for acute decompensated heart failure. Sci Rep. 2022, 12:2127. 10.1038/s41598-022-06032-x 10.1038/s41598-022-06032-x

[26]

Hariman RJ, Bremner S, Louie EK, et al.. Dose-response study of intravenous torsemide in congestive heart failure. Am Heart J. 1994, 128:352-7. 10.1016/0002-8703(94)90489-8 10.1016/0002-8703(94)90489-8

Metrics

1

Citations

26

References

Details

Published: Jul 16, 2023

Authors

Senthilnathan Mohanasundaram

Cite This Article

V. K Chopra, P. P Mohanan, Vijay Kher, et al. (2023). The Potential Role of Torsemide in Optimizing Loop Diuretic Therapy for Heart Failure Patients. Cureus. https://doi.org/10.7759/cureus.41957

The Potential Role of Torsemide in Optimizing Loop Diuretic Therapy for Heart Failure Patients

You May Also Like